Humoral Immune Response to Oncogenic Papillomavirus Types 16, 31, and 58 among Colombian Women with Normal Cytology
Keywords:
Uterine cervical neoplasms, papilloma, antibodies, natural historyAbstract
Objective: To profile IgG and IgA response to the VLP ( virus-like particles) of the human papillomaviruses (HPV) 16, 31 and 58 and to assess the possibility that they may be related to eliminating infection.
Methods: A group of 186 women with normal cytology, participants in a cohort study on the natural history of HPV infection, were selected. Three groups were evaluated: control (DNA HPV, n=146 negative), elimination (positive at outset and negative during follow-up, n=25), and persistance (positive during follow-up, n=15). The IgG and IgA antibodies against HPV-VLP 16, 31, and 58 were submitted to ELISA analysis.
Results: During the initial visit greater IgG antibody seroprevalence against HPV16-VLP was observed among the elimination group. This prevalence was combined with greater antibody levels in this group in comparison with the levels found among members of the persistence (mean DO405 nm 0.665 vs. 0.290, respectively). In contrast, during the fifth visit, there was greater IgG antibody seroprevalence against HPV-PLV 16 and 58 among the persistance group (p=0.001 and p=0.003, respectively). This response correlated with greater anitbody levels on this visit (mean DO 405 nm 0.653 and 0.532, respectively) in comparison with the antibody levels observed on the first visit (mean DO 405 nm 0.290 and0.362, respectively).
Conclusion: High levels of IgG antibodies working against HPV 16 and 58 during infection phase may be associated with elimination of infection.
Author Biographies
Alba Lucía Cómbita, Instituto Nacional de Cancerología
Instituto Nacional de Cancerología. Bogotá, Colombia.
Mónica Molano, Instituto Nacional de Cancerología
Instituto Nacional de Cancerología. Bogotá, Colombia.
Nubia Muñoz, Instituto Nacional de Cancerología
Instituto Nacional de Cancerología. Bogotá, Colombia.
María Mercedes Bravo, Instituto Nacional de Cancerología
Instituto Nacional de Cancerología. Bogotá, Colombia.
References
Muñoz N, Bosch FX, de San José, Tafur L, Izarzugaza I, Gili M, et al. The causal link between human papillomavirus and invasive cervical cancer: a population-based case-control study in Colombia and Spain. Int J Cancer. 1992;52(5):743-9.
https://doi.org/10.1002/ijc.2910520513
Piñeros M, Murillo RH. Incidencia de cancer en Colombia: importancia de las fuentes de información en la obtención de cifras estimativas. Rev Colomb Cancerol. 2004;8(1):5-14.
Bosch FX, Lorincz A, Muñoz N, Meijer CJ, Shah KV. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol. 2002;55(4):244-65.
https://doi.org/10.1136/jcp.55.4.244
Muñoz N. Human papillomavirus and cancer: the epidemiological evidence. J Clin Virol. 2000;19(1-2):1-5.
https://doi.org/10.1016/S1386-6532(00)00125-6
Wang SS, Zuna RE, Wentzensen N, Dunn ST, Sherman ME, Gold MA, et al. Human papillomavirus cofactors by disease progression and human papillomavirus types in the study to understand cervical cancer early endpoints and determinants. Cancer Epidemiol Biomarkers Prev. 2009;18(1):113-20.
https://doi.org/10.1158/1055-9965.EPI-08-0591
Wang SS, Schiffman M, Shields TS, Herrero R, Hildesheim A, Bratti MC, et al. Seroprevalence of human papillomavirus- 16, -18, -31, and -45 in a population-based cohort of 10000 women in Costa Rica. Br J Cancer. 2003;89(7):1248-54.
https://doi.org/10.1038/sj.bjc.6601272
Ho GY, Bierman R, Beardsley L, Chang CJ, Burk RD. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med. 1998;338(7):423-8.
https://doi.org/10.1056/NEJM199802123380703
Ho GY, Studentsov YY, Bierman R, Burk RD. Natural history of human papillomavirus type 16 virus-like particle antibodies in young women. Cancer Epidemiol Biomarkers Prev. 2004;13(1):110-6.
https://doi.org/10.1158/1055-9965.EPI-03-0191
Moscicki AB. HPV infections in adolescents. Dis Markers. 2007;23(4):229-34.
https://doi.org/10.1155/2007/136906
Fukuchi E, Sawaya GF, Chirenje M, Magure T, Tuveson J, Ma Y, et al. Cervical human papillomavirus incidence and persistence in a cohort of HIV-negative women in Zimbabwe. Sex Transm Dis. 2009;36(5):305-11.
https://doi.org/10.1097/OLQ.0b013e318194eb76
Moscicki AB, Shiboski S, Broering J, Powell K, Clayton L, Jay N, et al. The natural history of human papillomavirus infection as measured by repeated DNA testing in adolescent and young women. J Pediatr. 1998;132(2):277-84.
https://doi.org/10.1016/S0022-3476(98)70445-7
Muñoz N, Hernández-Suarez G, Méndez F, Molano M, Posso H, Moreno V, et al. Persistence of HPV infection and risk of high-grade cervical intraepithelial neoplasia in a cohort of Colombian women. Br J Cancer. 2009;100(7):1184-90.
https://doi.org/10.1038/sj.bjc.6604972
Palefsky J. Human papillomavirus infection among HIV-infected individuals. Implications for development of malignant tumors. Hematol Oncol Clin North Am. 1991;5(2):357-70.
https://doi.org/10.1016/S0889-8588(18)30447-7
Palefsky JM, Holly EA. Chapter 6: Immunosuppression and co-infection with HIV. J Natl Cancer Inst Monogr. 2003;(31):41-6.
https://doi.org/10.1093/oxfordjournals.jncimonographs.a003481
Petry KU, Scheffel D, Bode U, Gabrysiak T, Kochel H, Kupsch E, et al. Cellular immunodeficiency enhances the progression of human papillomavirus-associated cervical lesions. Int J Cancer. 1994;57(6):836-40.
https://doi.org/10.1002/ijc.2910570612
Silverberg MJ, Schneider MF, Silver B, Anastos KM, Burk RD, Minkoff H, et al. Serological detection of human papillomavirus type 16 infection in human immunodeficiency virus (HIV)-positive and high-risk HIV-negative women. Clin Vaccine Immunol. 2006;13(4):511-9.
https://doi.org/10.1128/CVI.13.4.511-519.2006
de Gruijl TD, Bontkes HJ, Walboomers JM, Coursaget P, Stukart MJ, Dupuy C, et al. Immune responses against human papillomavirus (HPV) type 16 virus-like particles in a cohort study of women with cervical intraepithelial neoplasia. I. Differential T-helper and IgG responses in relation to HPV infection and disease outcome. J Gen Virol. 1999;80 ( Pt 2):399-408.
https://doi.org/10.1099/0022-1317-80-2-399
Carter JJ, Koutsky LA, Hughes JP, Lee SK, Kuypers J, Kiviat N, et al. Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection. J Infect Dis. 2000;181(6):1911-9.
https://doi.org/10.1086/315498
Onda T, Carter JJ, Koutsky LA, Hughes JP, Lee SK, Kuypers J, et al. Characterization of IgA response among women with incident HPV 16 infection. Virology. 2003;312(1):213-21.
https://doi.org/10.1016/S0042-6822(03)00196-X
Wang ZH, Kjellberg L, Abdalla H, Wiklund F, Eklund C, Knekt P, et al. Type specificity and significance of different isotypes of serum antibodies to human papillomavirus capsids. J Infect Dis. 2000;181(2):456-62.
https://doi.org/10.1086/315232
Molano M, Posso H, Weiderpass E, van den Brule AJ, Ronderos M, Franceschi S, et al. Prevalence and determinants of HPV infection among Colombian women with normal cytology. Br J Cancer. 2002;87(3):324-33.
https://doi.org/10.1038/sj.bjc.6600442
Cómbita AL, Touze A, Bousarghin L, Sizaret PY, Muñoz N, Coursaget P. Gene transfer using human papillomavirus pseudovirions varies according to virus genotype and requires cell surface heparan sulfate. FEMS Microbiol Lett. 2001;204(1):183-8.
https://doi.org/10.1111/j.1574-6968.2001.tb10883.x
Cómbita AL, Bravo MM, Touze A, Orozco O, Coursaget P. Serologic response to human oncogenic papillomavirus types 16, 18, 31, 33, 39, 58 and 59 virus-like particles in colombian women with invasive cervical cancer. Int J Cancer. 2002;97(6):796-803.
https://doi.org/10.1002/ijc.10153
Molano M, Van den BA, Plummer M, Weiderpass E, Posso H, Arslan A, et al. Determinants of clearance of human papillomavirus infections in Colombian women with normal cytology: a population-based, 5-year follow-up study. Am J Epidemiol. 2003;158(5):486-94.
https://doi.org/10.1093/aje/kwg171
Marais DJ, Constant D, Allan B, Carrara H, Hoffman M, Shapiro S, et al. Cervical human papillomavirus (HPV) infection and HPV type 16 antibodies in South African women. J Clin Microbiol. 2008;46(2):732-9.
https://doi.org/10.1128/JCM.01322-07
Viscidi RP, Schiffman M, Hildesheim A, Herrero R, Castle PE, Bratti MC, et al. Seroreactivity to human papillomavirus (HPV) types 16, 18, or 31 and risk of subsequent HPV infection: results from a population-based study in Costa Rica. Cancer Epidemiol Biomarkers Prev. 2004;13(2):324-7.
https://doi.org/10.1158/1055-9965.EPI-03-0166
Kirnbauer R, Hubbert NL, Wheeler CM, Becker TM, Lowy DR, Schiller JT. A virus-like particle enzyme-linked immunosorbent assay detects serum antibodies in a majority of women infected with human papillomavirus type 16. J Natl Cancer Inst. 1994;86(7):494-9.
https://doi.org/10.1093/jnci/86.7.494
Nakagawa M, Viscidi R, Deshmukh I, Costa MD, Palefsky JM, Farhat S, et al. Time course of humoral and cellmediated immune responses to human papillomavirus type 16 in infected women. Clin Diagn Lab Immunol. 2002;9(4):877-82.
https://doi.org/10.1128/CDLI.9.4.877-882.2002
Wideroff L, Schiffman MH, Hoover R, Tarone RE, Nonnenmacher B, Hubbert N, et al. Epidemiologic determinants of seroreactivity to human papillomavirus (HPV) type 16 virus-like particles in cervical HPV-16 DNA-positive andnegative women. J Infect Dis. 1996;174(5):937-43.
https://doi.org/10.1093/infdis/174.5.937
Wideroff L, Schiffman MH, Nonnenmacher B, Hubbert N, Kirnbauer R, Greer CE, et al. Evaluation of seroreactivity to human papillomavirus type 16 virus-like particles in an incident case-control study of cervical neoplasia. J Infect Dis. 1995;172(6):1425-30.
https://doi.org/10.1093/infdis/172.6.1425
Ho GY, Studentsov Y, Hall CB, Bierman R, Beardsley L, Lempa M, et al. Risk factors for subsequent cervicovaginal human papillomavirus (HPV) infection and the protective role of antibodies to HPV-16 virus-like particles. J Infect Dis. 2002;186(6):737-42.
https://doi.org/10.1086/342972
Harro CD, Pang YY, Roden RB, Hildesheim A, Wang Z, Reynolds MJ, et al. Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine. J Natl Cancer Inst. 2001;93(4):284-92.
https://doi.org/10.1093/jnci/93.4.284
Joura EA, Kjaer SK, Wheeler CM, Sigurdsson K, Iversen OE, Hernandez-Avila M, et al. HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccine. Vaccine. 2008;26(52):6844-51.
https://doi.org/10.1016/j.vaccine.2008.09.073
Koutsky LA, Ault KA, Wheeler CM, Brown DR, Barr E, Alvarez FB, et al. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med. 2002;347(21):1645-51.
https://doi.org/10.1056/NEJMoa020586
Bontkes HJ, de Gruijl TD, Walboomers JM, Schiller JT, Dillner J, Helmerhorst TJ, et al. Immune responses against human papillomavirus (HPV) type 16 virus-like particles in a cohort study of women with cervical intraepithelial neoplasia. II. Systemic but not local IgA responses correlate with clearance of HPV-16. J Gen Virol. 1999;80 ( Pt 2):409-17.
https://doi.org/10.1099/0022-1317-80-2-409
Studentsov YY, Ho GY, Marks MA, Bierman R, Burk RD. Polymer-based enzyme-linked immunosorbent assay using human papillomavirus type 16 (HPV16) virus-like particles detects HPV16 clade-specific serologic responses. J Clin Microbiol. 2003;41(7):2827-34.
How to Cite
Downloads
Downloads
Published
Issue
Section
License
Todos los derechos reservados.
